- Home
- NRBO
as 11-21-2024 4:00pm EST
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 27.9M | IPO Year: | N/A |
| Target Price: | $10.00 | AVG Volume (30 days): | 36.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.08 - $6.75 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of NeuroBo Pharmaceuticals Inc. (NRBO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| DONG-A ST CO., LTD | NRBO | 10% Owner | Sep 18 '24 | Sell | $3.75 | 407 | $1,526.25 | 5,347,792 |
Latest NeuroBo Pharmaceuticals Inc. News
NRBO Breaking Stock News: Dive into NRBO Ticker-Specific Updates for Smart Investing
PR Newswire
4 days ago
NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases
GlobeNewswire
7 days ago
Life Sciences Investor Forum: Presentations Now Available for Online Viewing
PR Newswire
9 days ago
NeuroBo Pharmaceuticals to Participate in Investor Conferences in November
Zacks Small Cap Research
9 days ago
NRBO: Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024...
Zacks Small Cap Research
9 days ago
NRBO: Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024
GlobeNewswire
10 days ago
Life Sciences Investor Forum Agenda Announced for November 14th
PR Newswire
15 days ago
NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update
PR Newswire
18 days ago
NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
Compare NRBO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NRBO NeuroBo Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.